Project Grant DP2GM154019
Award Date
9/6/23
Completion Date
8/31/26
Dollars Obligated
$1.4M
Federal Agency
National Institute of General Medical Sciences
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $627,422 to the Regents of the University of Michigan to develop an engineered commensal E. coli strain that can neutralize the carcinogenic bacterial toxin colibactin and reduce tumorigenesis associated with colibactin-producing bacteria. The 5-year research project aims to optimize the surface display of the colibactin-inactivating enzyme ClbS on E. coli, evaluate the protective...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) in the amount of $400,890 provides funding for research on microbiome-mediated modulation of immune checkpoint molecules in colorectal cancer. The research aims to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate how the gut microbiome impacts immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to identify gut microbiome genes and metabolic pathways that impact amino acid homeostasis and the tumor microenvironment, with the goal of developing a synthetic microbial community to prevent and treat cancer. The $606,839 award to Weill Medical College of Cornell University will support a 5-year project to combine bioinformatics, metabolomics, bacterial genetics, and...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $422,931 to the University of Colorado-Denver to conduct research on characterizing the role of specialized microbial metabolites in shaping the structure and function of the human microbiome. The research aims to elucidate how these metabolite-driven microbial interactions influence community dynamics and susceptibility to...
This $109,255 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to determine how the material state of protein complexes influences mechanisms of protein quality control in bacteria, and to develop minimal positioning systems for studying and manipulating bacterial protein condensates. The award aims to advance the understanding of differences in principles governing...
This $253,405 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at Columbia University to identify mechanisms by which bacteria, specifically E. coli, can selectively colonize tumor tissue and be leveraged as vehicles for cancer therapy. The goal is to conduct comprehensive screens to understand the pathways enabling tumor-specific bacterial colonization, which can then be manipulated to improve the targeting and delivery of...
This $842,151 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an improved, low-endotoxin E. coli strain for the production of biological products such as recombinant proteins and plasmid DNA. The awardee, Scarab Genomics LLC, a biotechnology company in Madison, Wisconsin, will use genetic engineering techniques to substantially lower the level of contaminating endotoxin...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to enhance the colonization of the probiotic bacterium E. coli Nissle 1917 (ECN) using CRISPR-Cas immunity. The $548,802 award, provided to Ancilia Biosciences Inc., will investigate how phage predation can limit the engraftment and therapeutic efficacy of live biotherapeutic products...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $492,000.00 to The Trustees of Princeton University over a 5-year period from September 1, 2024 to August 31, 2029. The funding will support research aimed at accessing and expanding the chemical space of microbial and microbiome natural products. Key objectives include: (1) eliciting cryptic metabolites from diverse microbial genera,...
The National Cancer Institute (NCI) awarded a $179,988 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Leland Stanford Junior University (Stanford University) for the project "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer." The goal is to identify bacterial functions that can enhance response to immune checkpoint blockade (ICB) cancer immunotherapy. The project will leverage metagenomic data analysis, genetic engineering of...